

# Sanjay Awasthi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4892143/publications.pdf>

Version: 2024-02-01

239  
papers

10,255  
citations

29994

54  
h-index

46693

89  
g-index

242  
all docs

242  
docs citations

242  
times ranked

8976  
citing authors

#	ARTICLE	IF	CITATIONS
1	Rlip Depletion Alters Oncogene Transcription at Multiple Distinct Regulatory Levels. <i>Cancers</i> , 2022, 14, 527.	1.7	0
2	Case report of recurrent fibromatosis with laryngeal involvement: Treatment based on network analyses of NGS data. <i>Molecular and Clinical Oncology</i> , 2022, 16, 73.	0.4	2
3	Targeting RLIP with CRISPR/Cas9 controls tumor growth. <i>Carcinogenesis</i> , 2021, 42, 48-57.	1.3	15
4	Haploinsufficiency Interactions of RALBP1 and TP53 in Carcinogenesis. <i>Cancers</i> , 2021, 13, 255.	1.7	1
5	Prevention of mammary carcinogenesis in MMTV $\alpha$ -neu mice by targeting RLIP. <i>Molecular Carcinogenesis</i> , 2021, 60, 213-223.	1.3	2
6	RLIP depletion induces apoptosis associated with inhibition of JAK2/STAT3 signaling in melanoma cells. <i>Carcinogenesis</i> , 2021, 42, 742-752.	1.3	2
7	Therapeutic Potential of Rlip Loss on Atopic Dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, AB29.	1.5	0
8	Activating p53 function by targeting RLIP. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188512.	3.3	2
9	Haploinsufficiency Interactions between RALBP1 and p53 in ERBB2 and PyVT Models of Mouse Mammary Carcinogenesis. <i>Cancers</i> , 2021, 13, 3329.	1.7	5
10	Targeting the mercapturic acid pathway for the treatment of melanoma. <i>Cancer Letters</i> , 2021, 518, 10-22.	3.2	5
11	Dietary supplementation with sulforaphane ameliorates skin aging through activation of the Keap1-Nrf2 pathway. <i>Journal of Nutritional Biochemistry</i> , 2021, 98, 108817.	1.9	11
12	RALBP1 in Oxidative Stress and Mitochondrial Dysfunction in Alzheimer's Disease. <i>Cells</i> , 2021, 10, 3113.	1.8	12
13	Anticancer Activity of $\omega$ -6 Fatty Acids through Increased 4-HNE in Breast Cancer Cells. <i>Cancers</i> , 2021, 13, 6377.	1.7	6
14	SOX9: The master regulator of cell fate in breast cancer. <i>Biochemical Pharmacology</i> , 2020, 174, 113789.	2.0	47
15	RLIP controls receptor-ligand signaling by regulating clathrin-dependent endocytosis. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1873, 188337.	3.3	6
16	Sulforaphane prevents age-associated cardiac and muscular dysfunction through Nrf2 signaling. <i>Aging Cell</i> , 2020, 19, e13261.	3.0	64
17	Therapeutic targeting of miRNA-216b in cancer. <i>Cancer Letters</i> , 2020, 484, 16-28.	3.2	12
18	Rlip Depletion Suppresses Growth of Breast Cancer. <i>Cancers</i> , 2020, 12, 1446.	1.7	7

#	ARTICLE	IF	CITATIONS
19	Association of TGF- $\beta$ 1 Polymorphisms with Breast Cancer Risk: A Meta-Analysis of Case-Control Studies. <i>Cancers</i> , 2020, 12, 471.	1.7	5
20	Multi-Omic Analysis Reveals Different Effects of Sulforaphane on the Microbiome and Metabolome in Old Compared to Young Mice. <i>Microorganisms</i> , 2020, 8, 1500.	1.6	14
21	Chromosomal alterations of pediatric malignancy in a West Texas population. <i>Southwest Respiratory and Critical Care Chronicles</i> , 2020, 8, 7-20.	0.0	1
22	Notch signaling in breast cancer: From pathway analysis to therapy. <i>Cancer Letters</i> , 2019, 461, 123-131.	3.2	69
23	Topical 2-hydroxyflavanone for Cutaneous Melanoma. <i>Cancers</i> , 2019, 11, 1556.	1.7	13
24	Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells. <i>Breast Cancer Research</i> , 2019, 21, 104.	2.2	45
25	RLIP inhibition suppresses breast-to-lung metastasis. <i>Cancer Letters</i> , 2019, 447, 24-32.	3.2	16
26	Synergistic efficacy of RLIP inhibition and 2-hydroxyflavanone against DMBA-induced mammary carcinogenesis in SENCAR mice. <i>Molecular Carcinogenesis</i> , 2019, 58, 1438-1449.	1.3	13
27	RLIP: An existential requirement for breast carcinogenesis. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 281-288.	3.3	9
28	2-Hydroxyflavanone induced changes in the proteomic profile of breast cancer cells. <i>Journal of Proteomics</i> , 2019, 192, 233-245.	1.2	10
29	Daratumumab-Related Hematological Toxicities in Patients with Multiple Myeloma: A Combined Analysis of Five Phase III Randomized Controlled Trials. <i>Blood</i> , 2019, 134, 3485-3485.	0.6	2
30	Incidence of Second Primary Malignancies and Peripheral Sensory Neuropathy in Patients with Multiple Myeloma Receiving Daratumumab Containing Regimen. <i>Blood</i> , 2019, 134, 5550-5550.	0.6	2
31	Tolerability in Patients with Multiple Myeloma Treated with Daratumumab: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials. <i>Blood</i> , 2019, 134, 1873-1873.	0.6	1
32	Incidence of Serious Adverse Events, Pneumonitis, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Treated with Phosphatidylinositol 3-Kinase (PI3K) Inhibitors. <i>Blood</i> , 2019, 134, 798-798.	0.6	2
33	A structured algorithm for judicious use of antibody test in diagnosis of heparin-induced thrombocytopenia (HIT). <i>Journal of Clinical Oncology</i> , 2019, 37, 314-314.	0.8	0
34	Efficacy of Ibrutinib in Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Combined Analysis of Four Phase III Randomized Controlled Trials. <i>Blood</i> , 2019, 134, 5481-5481.	0.6	0
35	Performance of the New Automated Latex Immunoturbidometric Assay in the Diagnosis of Heparin Induced Thrombocytopenia: A Single Institution Experience. <i>Blood</i> , 2019, 134, 4689-4689.	0.6	0
36	Incidence of High-Grade Hematologic Toxicities and Hypertension in Patients with Hematological Malignancies Treated with Ibrutinib. <i>Blood</i> , 2019, 134, 5876-5876.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Rlip depletion prevents spontaneous neoplasia in TP53 null mice. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 3918-3923.	3.3	29
38	Translational opportunities for broad-spectrum natural phytochemicals and targeted agent combinations in breast cancer. International Journal of Cancer, 2018, 142, 658-670.	2.3	21
39	Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage III-IV melanoma. Melanoma Research, 2018, 28, 44-51.	0.6	31
40	Oxidative stress and dietary phytochemicals: Role in cancer chemoprevention and treatment. Cancer Letters, 2018, 413, 122-134.	3.2	400
41	NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma. Cancer, 2018, 124, 4332-4341.	2.0	15
42	Metastasis of breast tumor cells to brain is suppressed by targeting RLIP alone and in combination with 2-Hydroxyflavanone. Cancer Letters, 2018, 438, 144-153.	3.2	13
43	2-Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76. Molecular Carcinogenesis, 2018, 57, 1751-1762.	1.3	22
44	Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model. PLoS ONE, 2018, 13, e0193918.	1.1	65
45	2-Hydroxyflavanone effectively targets RLIP76-mediated drug transport and regulates critical signaling networks in breast cancer. Oncotarget, 2018, 9, 18053-18068.	0.8	21
46	Anticancer activity of 2-hydroxyflavanone towards lung cancer. Oncotarget, 2018, 9, 36202-36219.	0.8	22
47	Effective prevention of cancer in p53 null mice by depleting Rlip.. Journal of Clinical Oncology, 2018, 36, e13540-e13540.	0.8	1
48	Incidence of pneumonitis in patients with solid tumors treated with everolimus: A systematic review and meta-analysis of randomized controlled trials.. Journal of Clinical Oncology, 2018, 36, e22220-e22220.	0.8	0
49	Risk of hematological and gastrointestinal toxicities in patients with advanced neuroendocrine tumors treated with everolimus: A meta-analysis of phase 3 randomized controlled trials.. Journal of Clinical Oncology, 2018, 36, e16184-e16184.	0.8	0
50	Risk of health-related quality of life events and pulmonary toxicities in patients with advanced neuroendocrine tumors treated with everolimus: A meta-analysis of phase 3 randomized controlled trials.. Journal of Clinical Oncology, 2018, 36, e16185-e16185.	0.8	0
51	Risk of hematological toxicities in patients with advanced breast cancer treated with everolimus: A meta-analysis of phase 3 randomized controlled trials.. Journal of Clinical Oncology, 2018, 36, e13087-e13087.	0.8	0
52	Risk of gastrointestinal and hepatic toxicities in patients with advanced breast cancer treated with everolimus: A meta-analysis of phase 3 randomized controlled trials.. Journal of Clinical Oncology, 2018, 36, e22215-e22215.	0.8	0
53	A systematic review and meta-analysis of randomized controlled trials to evaluate the risk of hypophosphatemia, hypertension, and hematological toxicities in patients with cancer treated with regorafenib.. Journal of Clinical Oncology, 2018, 36, e22218-e22218.	0.8	0
54	A systematic review and meta-analysis of randomized controlled trials to evaluate the risk of pulmonary toxicities in patients with advanced breast cancer treated with everolimus.. Journal of Clinical Oncology, 2018, 36, e13086-e13086.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Risk of health-related quality of life and metabolic events and pulmonary toxicities in patients with advanced renal cell carcinoma treated with everolimus: A meta-analysis of phase 3 randomized controlled trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16551-e16551.	0.8	0
56	A Restructured Approach to Diagnosis of Heparin Induced Thrombocytopenia in a Large Tertiary Hospital. <i>Blood</i> , 2018, 132, 3525-3525.	0.6	1
57	A systematic review and combined analysis of phase III trials to evaluate the safety of adjuvant sunitinib in patients with high risk renal cell carcinoma after nephrectomy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 214-214.	0.8	2
58	Discontinuation of poly(adenosine diphosphate-ribose) polymerase inhibitors due to adverse events in patients with recurrent ovarian cancer: A meta-analysis of three phase III trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 118-118.	0.8	1
59	Discontinuation of adjuvant sunitinib due to adverse events in patients with high-risk renal cell carcinoma after nephrectomy: A combined analysis of phase III trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 215-215.	0.8	1
60	Aldose reductase inhibitor increases doxorubicin-sensitivity of colon cancer cells and decreases cardiotoxicity. <i>Scientific Reports</i> , 2017, 7, 3182.	1.6	55
61	Targeting the mercapturic acid pathway and vicenin-2 for prevention of prostate cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 167-175.	3.3	22
62	RLIP76 Inhibition: A Promising Developmental Therapy for Neuroblastoma. <i>Pharmaceutical Research</i> , 2017, 34, 1673-1682.	1.7	8
63	Regulatory roles of glutathione-S-transferases and 4-hydroxynonenal in stress-mediated signaling and toxicity. <i>Free Radical Biology and Medicine</i> , 2017, 111, 235-243.	1.3	45
64	Didymin: an orally active citrus flavonoid for targeting neuroblastoma. <i>Oncotarget</i> , 2017, 8, 29428-29441.	0.8	20
65	2'-Hydroxyflavanone: A novel strategy for targeting breast cancer. <i>Oncotarget</i> , 2017, 8, 75025-75037.	0.8	35
66	PS01.34: Differential Modulation of Glutathione Metabolism in Adeno and Squamous NSCLC by 2HF. <i>Journal of Thoracic Oncology</i> , 2016, 11, S289-S290.	0.5	0
67	MINI01.05: RALPB1 Mediate ALK Resistance in Non-“Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, S258-S259.	0.5	0
68	Glutathione Conjugate Transporter RLIP76. , 2016, , 1922-1925.		0
69	2â€™-Hydroxyflavanone: A promising molecule for kidney cancer prevention. <i>Biochemical Pharmacology</i> , 2015, 96, 151-158.	2.0	15
70	RLIP76 Targeted Therapy for Kidney Cancer. <i>Pharmaceutical Research</i> , 2015, 32, 3123-3136.	1.7	12
71	SR4 Uncouples Mitochondrial Oxidative Phosphorylation, Modulates AMP-dependent Kinase (AMPK)-Mammalian Target of Rapamycin (mTOR) Signaling, and Inhibits Proliferation of HepG2 Hepatocarcinoma Cells. <i>Journal of Biological Chemistry</i> , 2015, 290, 30321-30341.	1.6	31
72	Antioxidant role of glutathione S-transferases: 4-Hydroxynonenal, a key molecule in stress-mediated signaling. <i>Toxicology and Applied Pharmacology</i> , 2015, 289, 361-370.	1.3	152

#	ARTICLE	IF	CITATIONS
73	RLIP76 regulates Arf6-dependent cell spreading and migration by linking ARNO with activated R-Ras at recycling endosomes. <i>Biochemical and Biophysical Research Communications</i> , 2015, 467, 785-791.	1.0	18
74	Lens specific RLIP76 transgenic mice show a phenotype similar to microphthalmia. <i>Experimental Eye Research</i> , 2014, 118, 125-134.	1.2	2
75	LR-90 prevents methylglyoxal-induced oxidative stress and apoptosis in human endothelial cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2014, 19, 776-788.	2.2	55
76	Abstract 2149: Novel compound 1, 3-bis (3, 5-dichlorophenyl) urea inhibits lung cancer progression. , 2014, , .		1
77	Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma. <i>Molecular Carcinogenesis</i> , 2013, 52, 39-48.	1.3	26
78	Novel compound 1,3-bis (3,5-dichlorophenyl) urea inhibits lung cancer progression. <i>Biochemical Pharmacology</i> , 2013, 86, 1664-1672.	2.0	10
79	P300 regulates the human RLIP76 promoter activity and gene expression. <i>Biochemical Pharmacology</i> , 2013, 85, 1203-1211.	2.0	13
80	Regression of Lung Cancer by Hypoxia-Sensitizing Ruthenium Polypyridyl Complexes. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 643-653.	1.9	57
81	RLIP76 Protein Knockdown Attenuates Obesity Due to a High-fat Diet. <i>Journal of Biological Chemistry</i> , 2013, 288, 23394-23406.	1.6	22
82	4-Hydroxynonenal Induces G2/M Phase Cell Cycle Arrest by Activation of the Ataxia Telangiectasia Mutated and Rad3-related Protein (ATR)/Checkpoint Kinase 1 (Chk1) Signaling Pathway. <i>Journal of Biological Chemistry</i> , 2013, 288, 20532-20546.	1.6	45
83	Proteomic Analysis of Signaling Network Regulation in Renal Cell Carcinomas with Differential Hypoxia-Inducible Factor-2 $\alpha$ Expression. <i>PLoS ONE</i> , 2013, 8, e71654.	1.1	10
84	COH-SR4 Reduces Body Weight, Improves Glycemic Control and Prevents Hepatic Steatosis in High Fat Diet-Induced Obese Mice. <i>PLoS ONE</i> , 2013, 8, e83801.	1.1	24
85	Role of SMC1 in Overcoming Drug Resistance in Triple Negative Breast Cancer. <i>PLoS ONE</i> , 2013, 8, e64338.	1.1	24
86	Didymin Induces Apoptosis by Inhibiting N-Myc and Upregulating RKIP in Neuroblastoma. <i>Cancer Prevention Research</i> , 2012, 5, 473-483.	0.7	41
87	The expression and function of vascular endothelial growth factor in retinal pigment epithelial (RPE) cells is regulated by 4-hydroxynonenal (HNE) and glutathione S-transferaseA4-4. <i>Biochemical and Biophysical Research Communications</i> , 2012, 417, 346-351.	1.0	29
88	RALBP1/RLIP76 Depletion in Mice Suppresses Tumor Growth by Inhibiting Tumor Neovascularization. <i>Cancer Research</i> , 2012, 72, 5165-5173.	0.4	48
89	1,3-Bis(3,5-dichlorophenyl) urea compound 1-COH-SR4 <sup>TM</sup> inhibits proliferation and activates apoptosis in melanoma. <i>Biochemical Pharmacology</i> , 2012, 84, 1419-1427.	2.0	17
90	RLIP76 Regulates PI3K/Akt Signaling and Chemo-Radiotherapy Resistance in Pancreatic Cancer. <i>PLoS ONE</i> , 2012, 7, e34582.	1.1	38

#	ARTICLE	IF	CITATIONS
91	Association of Rash With Outcomes in a Randomized Phase II Trial Evaluating Cetuximab in Combination With Mitoxantrone Plus Prednisone After Docetaxel for Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 6-14.	0.9	28
92	Role of 4-hydroxynonenal in chemopreventive activities of sulforaphane. <i>Free Radical Biology and Medicine</i> , 2012, 52, 2177-2185.	1.3	19
93	Novel Anti-cancer Compounds for Developing Combinatorial Therapies to Target Anoikis-Resistant Tumors. <i>Pharmaceutical Research</i> , 2012, 29, 621-636.	1.7	18
94	Role of 4-hydroxynonenal in epidermal growth factor receptor-mediated signaling in retinal pigment epithelial cells. <i>Experimental Eye Research</i> , 2011, 92, 147-154.	1.2	32
95	RLIP76, a Glutathione-Conjugate Transporter, Plays a Major Role in the Pathogenesis of Metabolic Syndrome. <i>PLoS ONE</i> , 2011, 6, e24688.	1.1	44
96	Anti-cancer effects of novel flavonoid vicenin-2 as a single agent and in synergistic combination with docetaxel in prostate cancer. <i>Biochemical Pharmacology</i> , 2011, 82, 1100-1109.	2.0	97
97	The sensors and regulators of cell matrix surveillance in anoikis resistance of tumors. <i>International Journal of Cancer</i> , 2011, 128, 743-752.	2.3	68
98	Targeting p53-Null Neuroblastomas through RLIP76. <i>Cancer Prevention Research</i> , 2011, 4, 879-889.	0.7	20
99	2'-Hydroxyflavanone inhibits proliferation, tumor vascularization and promotes normal differentiation in VHL-mutant renal cell carcinoma. <i>Carcinogenesis</i> , 2011, 32, 568-575.	1.3	34
100	Inhibition of aldose reductase prevents colon cancer metastasis. <i>Carcinogenesis</i> , 2011, 32, 1259-1267.	1.3	53
101	Glutathione-Conjugate Transport by RLIP76 Is Required for Clathrin-Dependent Endocytosis and Chemical Carcinogenesis. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 16-28.	1.9	54
102	Glutathione Conjugate Transporter RLIP76. , 2011, , 1559-1563.		0
103	Inhibition of mercapturic acid pathway-mediated disposal of 4-hydroxynonenal causes complete and sustained remission of human cancer xenografts in nude mice. <i>Indian Journal of Experimental Biology</i> , 2011, 49, 817-25.	0.5	3
104	Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. <i>International Journal of Cancer</i> , 2010, 126, 1327-1338.	2.3	53
105	RLIP76: A versatile transporter and an emerging target for cancer therapy. <i>Biochemical Pharmacology</i> , 2010, 79, 1699-1705.	2.0	44
106	A Central Role of RLIP76 in Regulation of Glycemic Control. <i>Diabetes</i> , 2010, 59, 714-725.	0.3	31
107	Mechanisms of 4-Hydroxy-2-nonenal Induced Pro- and Anti-Apoptotic Signaling. <i>Biochemistry</i> , 2010, 49, 6263-6275.	1.2	95
108	Role of Lipid Peroxidation in Cellular Responses to <sc>d</sc>,<sc>l</sc>-Sulforaphane, a Promising Cancer Chemopreventive Agent. <i>Biochemistry</i> , 2010, 49, 3191-3202.	1.2	31



#	ARTICLE	IF	CITATIONS
109	RLIP76: A Target for Kidney Cancer Therapy. <i>Cancer Research</i> , 2009, 69, 4244-4251.	0.4	62
110	Physiological and Pharmacological Significance of Glutathione-Conjugate Transport. <i>Journal of Toxicology and Environmental Health - Part B: Critical Reviews</i> , 2009, 12, 540-551.	2.9	27
111	Regression of prostate cancer xenografts by RLIP76 depletion. <i>Biochemical Pharmacology</i> , 2009, 77, 1074-1083.	2.0	55
112	hSET1: A novel approach for colon cancer therapy. <i>Biochemical Pharmacology</i> , 2009, 77, 1635-1641.	2.0	16
113	Increased expression of cdc2 inhibits transport function of RLIP76 and promotes apoptosis. <i>Cancer Letters</i> , 2009, 283, 152-158.	3.2	21
114	Role of RLIP76 in doxorubicin resistance in lung cancer (Review). <i>International Journal of Oncology</i> , 2009, 34, 1505-11.	1.4	36
115	The Role of RLIP76 in Dendritic Cell-Based Immunotherapies.. <i>Blood</i> , 2009, 114, 3689-3689.	0.6	0
116	Human GST5.8, Expressed in a Cell Cycle Specific Manner, May Offer a Method to Alter 4-Hydroxynonenal Concentrations of Philadelphia-Positive Chronic Myelogenous Leukemia Cells.. <i>Blood</i> , 2009, 114, 4260-4260.	0.6	0
117	Functional reconstitution of RLIP76 catalyzing ATP-dependent transport of glutathione-conjugates. <i>International Journal of Oncology</i> , 2009, 34, 191-9.	1.4	16
118	Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium. <i>Investigational New Drugs</i> , 2008, 26, 151-158.	1.2	6
119	The determination of glutathione-4-hydroxynonenal (GSHNE), E-4-hydroxynonenal (HNE), and E-1-hydroxynon-2-en-4-one (HNO) in mouse liver tissue by LC-ESI-MS. <i>Analytical and Bioanalytical Chemistry</i> , 2008, 392, 1325-1333.	1.9	27
120	RLIP76 in Defense of Radiation Poisoning. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 553-561.	0.4	50
121	Diminished drug transport and augmented radiation sensitivity caused by loss of RLIP76. <i>FEBS Letters</i> , 2008, 582, 3408-3414.	1.3	22
122	Self-regulatory role of 4-hydroxynonenal in signaling for stress-induced programmed cell death. <i>Free Radical Biology and Medicine</i> , 2008, 45, 111-118.	1.3	96
123	4-Hydroxynonenal induces p53-mediated apoptosis in retinal pigment epithelial cells. <i>Archives of Biochemistry and Biophysics</i> , 2008, 480, 85-94.	1.4	92
124	4-Hydroxynonenal Self-Limits Fas-Mediated DISC-Independent Apoptosis by Promoting Export of Daxx from the Nucleus to the Cytosol and Its Binding to Fas. <i>Biochemistry</i> , 2008, 47, 143-156.	1.2	63
125	Hsf-1 and POB1 Induce Drug Sensitivity and Apoptosis by Inhibiting Ralbp1. <i>Journal of Biological Chemistry</i> , 2008, 283, 19714-19729.	1.6	51
126	RLIP76 and Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 4372-4377.	3.2	76



#	ARTICLE	IF	CITATIONS
127	Glutathione Conjugate Transporter RLIP76. , 2008, , 1263-1263.		0
128	Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma. Leukemia and Lymphoma, 2007, 48, 1736-1744.	0.6	13
129	The Non-ABC Drug Transporter RLIP76 (RALBP-1) Plays a Major Role in the Mechanisms of Drug Resistance. Current Drug Metabolism, 2007, 8, 315-323.	0.7	46
130	Regression of Lung and Colon Cancer Xenografts by Depleting or Inhibiting RLIP76 (Ral-Binding Protein) Tj ETQq0 0.0 rgBT /Overlock 10	0.4	97
131	RALBP1/RLIP76 mediates multidrug resistance. International Journal of Oncology, 2007, , .	1.4	16
132	RLIP76 in AED drug resistance. Epilepsia, 2007, 48, 1218-1219.	2.6	8
133	Linking stress-signaling, glutathione metabolism, signaling pathways and xenobiotic transporters. Cancer and Metastasis Reviews, 2007, 26, 59-69.	2.7	40
134	On the diversity of biological therapeutics. Biologics: Targets and Therapy, 2007, 1, 183-4.	3.0	0
135	RALBP1/RLIP76 mediates multidrug resistance. International Journal of Oncology, 2007, 30, 139-44.	1.4	17
136	Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. International Journal of Oncology, 2007, 30, 717-25.	1.4	20
137	Therapeutic resistance in lung cancer. Expert Opinion on Drug Metabolism and Toxicology, 2006, 2, 753-777.	1.5	30
138	Regulation of CD95 (Fas) Expression and Fas-Mediated Apoptotic Signaling in HLE B-3 Cells by 4-Hydroxynonenal. Biochemistry, 2006, 45, 12253-12264.	1.2	46
139	Regression of Melanoma in a Murine Model by RLIP76 Depletion. Cancer Research, 2006, 66, 2354-2360.	0.4	97
140	Glutathione S-transferases as antioxidant enzymes: Small cell lung cancer (H69) cells transfected with hGSTA1 resist doxorubicin-induced apoptosis. Archives of Biochemistry and Biophysics, 2006, 452, 165-173.	1.4	47
141	Determinants of differential doxorubicin sensitivity between SCLC and NSCLC. FEBS Letters, 2006, 580, 2258-2264.	1.3	36
142	Mitogenic and drug-resistance mediating effects of PKC $\zeta$ require RLIP76. Biochemical and Biophysical Research Communications, 2006, 348, 722-727.	1.0	19
143	Aldose Reductase Regulates Growth Factor-Induced Cyclooxygenase-2 Expression and Prostaglandin E2 Production in Human Colon Cancer Cells. Cancer Research, 2006, 66, 9705-9713.	0.4	113
144	Mitogenic Responses of Vascular Smooth Muscle Cells to Lipid Peroxidation-derived Aldehyde 4-Hydroxy-trans-2-nonenal (HNE). Journal of Biological Chemistry, 2006, 281, 17652-17660.	1.6	132

#	ARTICLE	IF	CITATIONS
145	Glutathione-Conjugate Transport and Stress-Response Signaling. , 2006, , 231-256.		7
146	Enzymology of Glutathione S-Transferases. , 2006, , 339-358.		0
147	Depletion of RLIP76 sensitizes lung cancer cells to doxorubicin. <i>Biochemical Pharmacology</i> , 2005, 70, 481-488.	2.0	70
148	RLIP76 Is a Major Determinant of Radiation Sensitivity. <i>Cancer Research</i> , 2005, 65, 6022-6028.	0.4	85
149	POB1 over-expression inhibits RLIP76-mediated transport of glutathione-conjugates, drugs and promotes apoptosis. <i>Biochemical and Biophysical Research Communications</i> , 2005, 328, 1003-1009.	1.0	43
150	Depletion of 4-hydroxynonenal in hGSTA4-transfected HLE B-3 cells results in profound changes in gene expression. <i>Biochemical and Biophysical Research Communications</i> , 2005, 334, 425-432.	1.0	26
151	The role of PKC $\zeta$ and RLIP76 in transport-mediated doxorubicin-resistance in lung cancer. <i>FEBS Letters</i> , 2005, 579, 4635-4641.	1.3	29
152	RLIP76, a non-ABC transporter, and drug resistance in epilepsy. <i>BMC Neuroscience</i> , 2005, 6, 61.	0.8	74
153	Regulation of 4-hydroxynonenal Mediated Signaling By Glutathione S-transferases. <i>Methods in Enzymology</i> , 2005, 401, 379-407.	0.4	93
154	RLIP76 transports vinorelbine and mediates drug resistance in non-small cell lung cancer. <i>Cancer Research</i> , 2005, 65, 991-8.	0.4	64
155	Transfection with 4-hydroxynonenal-metabolizing glutathione S-transferase isozymes leads to phenotypic transformation and immortalization of adherent cells. <i>FEBS Journal</i> , 2004, 271, 1690-1701.	0.2	56
156	Physiological role of mGSTA4-4, a glutathione S-transferase metabolizing 4-hydroxynonenal: generation and analysis of mGsta4 null mouse. <i>Toxicology and Applied Pharmacology</i> , 2004, 194, 296-308.	1.3	133
157	Regulation of 4-hydroxynonenal-mediated signaling by glutathione S-transferases. <i>Free Radical Biology and Medicine</i> , 2004, 37, 607-619.	1.3	216
158	RLIP76 (RALBP1)-mediated transport of leukotriene C4 (LTC4) in cancer cells: Implications in drug resistance. <i>International Journal of Cancer</i> , 2004, 112, 934-942.	2.3	43
159	Identification of Membrane-Anchoring Domains of RLIP76 Using Deletion Mutant Analyses. <i>Biochemistry</i> , 2004, 43, 16243-16253.	1.2	48
160	Antioxidant Role of Glutathione S-Transferases: Protection Against Oxidant Toxicity and Regulation of Stress-Mediated Apoptosis. <i>Antioxidants and Redox Signaling</i> , 2004, 6, 289-300.	2.5	276
161	Transport of glutathione conjugates and chemotherapeutic drugs by RLIP76 (RALBP1): A novel link between G-protein and tyrosine kinase signaling and drug resistance. <i>International Journal of Cancer</i> , 2003, 106, 635-646.	2.3	110
162	Mechanisms and Physiological Significance of the Transport of the Glutathione Conjugate of 4-Hydroxynonenal in Human Lens Epithelial Cells. , 2003, 44, 3438.		18

#	ARTICLE	IF	CITATIONS
163	Role of 4-hydroxynonenal in stress-mediated apoptosis signaling. <i>Molecular Aspects of Medicine</i> , 2003, 24, 219-230.	2.7	156
164	Cells Preconditioned with Mild, Transient UVA Irradiation Acquire Resistance to Oxidative Stress and UVA-induced Apoptosis. <i>Journal of Biological Chemistry</i> , 2003, 278, 41380-41388.	1.6	84
165	Role of RLIP76 in lung cancer doxorubicin resistance: I. The ATPase activity of RLIP76 correlates with doxorubicin and 4-hydroxynonenal resistance in lung cancer cells. <i>International Journal of Oncology</i> , 2003, 22, 365.	1.4	16
166	Role of RLIP76 in lung cancer doxorubicin resistance: III. Anti-RLIP76 antibodies trigger apoptosis in lung cancer cells and synergistically increase doxorubicin cytotoxicity. <i>International Journal of Oncology</i> , 2003, 22, 721.	1.4	22
167	Role of RLIP76 in lung cancer doxorubicin resistance: II. Doxorubicin transport in lung cancer by RLIP76. <i>International Journal of Oncology</i> , 2003, 22, 713.	1.4	19
168	Lipid peroxidation and cell cycle signaling: 4-hydroxynonenal, a key molecule in stress mediated signaling.. <i>Acta Biochimica Polonica</i> , 2003, 50, 319-336.	0.3	212
169	Energy Dependent Transport of Xenobiotics and Its Relevance to Multidrug Resistance. <i>Current Cancer Drug Targets</i> , 2003, 3, 89-107.	0.8	39
170	Role of RLIP76 in lung cancer doxorubicin resistance: I. The ATPase activity of RLIP76 correlates with doxorubicin and 4-hydroxynonenal resistance in lung cancer cells. <i>International Journal of Oncology</i> , 2003, 22, 365-75.	1.4	22
171	Role of RLIP76 in lung cancer doxorubicin resistance: II. Doxorubicin transport in lung cancer by RLIP76. <i>International Journal of Oncology</i> , 2003, 22, 713-20.	1.4	28
172	Role of RLIP76 in lung cancer doxorubicin resistance: III. Anti-RLIP76 antibodies trigger apoptosis in lung cancer cells and synergistically increase doxorubicin cytotoxicity. <i>International Journal of Oncology</i> , 2003, 22, 721-32.	1.4	25
173	RLIP76, a Novel Transporter Catalyzing ATP-Dependent Efflux of Xenobiotics. <i>Drug Metabolism and Disposition</i> , 2002, 30, 1300-1310.	1.7	84
174	Membrane Association of Glutathione S-Transferase mGSTA4-4, an Enzyme That Metabolizes Lipid Peroxidation Products. <i>Journal of Biological Chemistry</i> , 2002, 277, 4232-4239.	1.6	60
175	Transport functions and physiological significance of 76 kDa Ral-binding GTPase activating protein (RLIP76).. <i>Acta Biochimica Polonica</i> , 2002, 49, 855-867.	0.3	21
176	Functional reconstitution of Ral-binding GTPase activating protein, RLIP76, in proteoliposomes catalyzing ATP-dependent transport of glutathione conjugate of 4-hydroxynonenal.. <i>Acta Biochimica Polonica</i> , 2002, 49, 693-701.	0.3	25
177	Protection of HLE B-3 cells against hydrogen peroxide- and naphthalene-induced lipid peroxidation and apoptosis by transfection with hGSTA1 and hGSTA2. <i>Investigative Ophthalmology and Visual Science</i> , 2002, 43, 434-45.	3.3	40
178	RLIP76 Is the Major ATP-Dependent Transporter of Glutathione-Conjugates and Doxorubicin in Human Erythrocytes. <i>Archives of Biochemistry and Biophysics</i> , 2001, 391, 171-179.	1.4	66
179	Transfection of mGSTA4 in HL-60 Cells Protects against 4-Hydroxynonenal-Induced Apoptosis by Inhibiting JNK-Mediated Signaling. <i>Archives of Biochemistry and Biophysics</i> , 2001, 392, 197-207.	1.4	114
180	Two Distinct 4-Hydroxynonenal Metabolizing Glutathione S-Transferase Isozymes Are Differentially Expressed in Human Tissues. <i>Biochemical and Biophysical Research Communications</i> , 2001, 282, 1268-1274.	1.0	59

#	ARTICLE	IF	CITATIONS
181	Functional Reassembly of ATP-Dependent Xenobiotic Transport by the N- and C-Terminal Domains of RLIP76 and Identification of ATP Binding Sequences. <i>Biochemistry</i> , 2001, 40, 4159-4168.	1.2	66
182	Role of Glutathione S-Transferases in Protection against Lipid Peroxidation. <i>Journal of Biological Chemistry</i> , 2001, 276, 19220-19230.	1.6	271
183	Accelerated Metabolism and Exclusion of 4-Hydroxynonenal through Induction of RLIP76 and hGST5.8 Is an Early Adaptive Response of Cells to Heat and Oxidative Stress. <i>Journal of Biological Chemistry</i> , 2001, 276, 41213-41223.	1.6	164
184	Curcumin-glutathione interactions and the role of human glutathione S-transferase P1-1. <i>Chemico-Biological Interactions</i> , 2000, 128, 19-38.	1.7	107
185	Novel Function of Human RLIP76: ATP-Dependent Transport of Glutathione Conjugates and Doxorubicin. <i>Biochemistry</i> , 2000, 39, 9327-9334.	1.2	163
186	Bilateral breast MALT lymphoma: a case report and review of the literature. <i>Annals of Hematology</i> , 2000, 79, 86-89.	0.8	20
187	Activity of Allelic Variants of Pi Class Human Glutathione S-Transferase Toward Chlorambucil. <i>Biochemical and Biophysical Research Communications</i> , 2000, 278, 258-262.	1.0	65
188	Attenuation of galactose cataract by low levels of dietary curcumin. <i>Nutrition Research</i> , 2000, 20, 515-526.	1.3	13
189	Dietary curcumin prevents ocular toxicity of naphthalene in rats. <i>Toxicology Letters</i> , 2000, 115, 195-204.	0.4	78
190	ATP-Dependent Colchicine Transport by Human Erythrocyte Glutathione Conjugate Transporter. <i>Toxicology and Applied Pharmacology</i> , 1999, 155, 215-226.	1.3	29
191	Role of Glutathione S-transferase 8-8 in Allylamine Resistance of Vascular Smooth Muscle Cells in Vitro. <i>Toxicology and Applied Pharmacology</i> , 1999, 158, 177-185.	1.3	24
192	The effect of curcumin on glutathione-linked enzymes in K562 human leukemia cells. <i>Toxicology Letters</i> , 1999, 109, 87-95.	0.4	43
193	The Role of Human Glutathione S-Transferases hGSTA1-1 and hGSTA2-2 in Protection against Oxidative Stress. <i>Archives of Biochemistry and Biophysics</i> , 1999, 367, 216-224.	1.4	114
194	Metabolic Fate of Glutathione Conjugate of Benzo[a]pyrene-(7R,8S)-diol (9S,10R)-epoxide in Human Liver. <i>Archives of Biochemistry and Biophysics</i> , 1999, 371, 340-344.	1.4	21
195	Effects of mGST A4 Transfection on 4-Hydroxynonenal-Mediated Apoptosis and Differentiation of K562 Human Erythroleukemia Cells. <i>Archives of Biochemistry and Biophysics</i> , 1999, 372, 29-36.	1.4	117
196	Glutathione S-Transferases of Rabbit Lung Macrophages. <i>Toxicology and Applied Pharmacology</i> , 1998, 148, 229-236.	1.3	12
197	The Role of Glutathione S-Transferases as a Defense against Reactive Electrophiles in the Blood Vessel Wall. <i>Toxicology and Applied Pharmacology</i> , 1998, 152, 83-89.	1.3	43
198	Gender-related differences in susceptibility of A/J mouse to benzo[a]pyrene-induced pulmonary and forestomach tumorigenesis. <i>Cancer Letters</i> , 1998, 128, 197-204.	3.2	40

#	ARTICLE	IF	CITATIONS
199	Mechanisms of anticarcinogenic properties of curcumin: the effect of curcumin on glutathione linked detoxification enzymes in rat liver. <i>International Journal of Biochemistry and Cell Biology</i> , 1998, 30, 445-456.	1.2	208
200	ATP-Dependent Human Erythrocyte Glutathione-Conjugate Transporter. II. Functional Reconstitution of Transport Activity. <i>Biochemistry</i> , 1998, 37, 5239-5248.	1.2	51
201	ATP-Dependent Human Erythrocyte Glutathione-Conjugate Transporter. I. Purification, Photoaffinity Labeling, and Kinetic Characteristics of ATPase Activity. <i>Biochemistry</i> , 1998, 37, 5231-5238.	1.2	47
202	ATP-dependent transport of glutathione conjugate of 7 $\beta$ ,8 $\alpha$ -dihydroxy-9 $\beta$ ,10 $\alpha$ -oxy-7,8,9,10-tetrahydrobenzo[a]pyrene in murine hepatic canalicular plasma membrane vesicles. <i>Biochemical Journal</i> , 1998, 332, 799-805.	1.7	16
203	DIFFERENTIAL CARCINOGENICITY OF BENZO[a]PYRENE IN MALE AND FEMALE CD-1 MOUSE LUNG. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 1997, 52, 45-62.	1.1	14
204	Mechanism of Differential Catalytic Efficiency of Two Polymorphic Forms of Human GlutathioneS-Transferase P1-1 in the Glutathione Conjugation of Carcinogenic Diol Epoxide of Chrysene. <i>Archives of Biochemistry and Biophysics</i> , 1997, 345, 32-38.	1.4	78
205	Active Site Architecture of Polymorphic Forms of Human GlutathioneS-Transferase P1-1 Accounts for Their Enantioselectivity and Disparate Activity in the Glutathione Conjugation of 7 $\beta$ ,8 $\alpha$ -Dihydroxy-9 $\beta$ ,10 $\alpha$ -oxy-7,8,9,10-tetrahydrobenzo(a)pyrene. <i>Biochemical and Biophysical Research Communications</i> , 1997, 235, 424-428.	1.0	82
206	Rat GST 8-8 is expressed predominantly in myeloid origin cells infiltrating the gravid uterus. <i>International Journal of Biochemistry and Cell Biology</i> , 1997, 29, 807-813.	1.2	3
207	Multiple transport proteins involved in the detoxification of endo- and xenobiotics. <i>Frontiers in Bioscience - Landmark</i> , 1997, 2, d427-437.	3.0	7
208	Increased Resistance to Oxidative Stress in Transfected Cultured Cells Overexpressing GlutathioneS-Transferase mGSTA4-4. <i>Toxicology and Applied Pharmacology</i> , 1997, 143, 221-229.	1.3	66
209	Induction of glutathioneS-transferase $\alpha$ as a bioassay for the evaluation of potency of inhibitors of benzo(a)pyrene-induced cancer in a murine model. , 1997, 73, 897-902.		69
210	A Glutathione S-transferases Isozyme (bGST 5.8) Involved in the Metabolism of 4-Hydroxy-2-trans-nonenal is Localized in Bovine Lens Epithelium. <i>Experimental Eye Research</i> , 1996, 63, 329-337.	1.2	19
211	Transfection of a 4-Hydroxynonenal Metabolizing GlutathioneS-Transferase Isozyme, Mouse GSTA4-4, Confers Doxorubicin Resistance to Chinese Hamster Ovary Cells. <i>Archives of Biochemistry and Biophysics</i> , 1996, 333, 214-220.	1.4	34
212	Purification and characterization of a 4-hydroxynonenal metabolizing glutathione S-transferase isozyme from bovine pulmonary microvessel endothelial cells. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1996, 1291, 182-188.	1.1	24
213	Purification and characterization of glutathione S-transferases of rat uterus. <i>International Journal of Biochemistry and Cell Biology</i> , 1996, 28, 1271-1283.	1.2	5
214	Curcumin protects against 4-hydroxy-2-trans-nonenal-induced cataract formation in rat lenses. <i>American Journal of Clinical Nutrition</i> , 1996, 64, 761-766.	2.2	119
215	Rabbit Aorta GlutathioneS-Transferases and Their Role in Bioactivation of Trinitroglycerin. <i>Toxicology and Applied Pharmacology</i> , 1996, 140, 378-386.	1.3	23
216	Modulation of doxorubicin cytotoxicity by ethacrynic acid. , 1996, 68, 333-339.		24

#	ARTICLE	IF	CITATIONS
217	Attenuation of 4-hydroxynonenal-induced cataractogenesis in rat lens by butylated hydroxytoluene. <i>Current Eye Research</i> , 1996, 15, 749-754.	0.7	24
218	Iron-Induced Lipid-Peroxidation in Rat Liver Is Accompanied by Preferential Induction of Glutathione S-Transferase 8-8 Isozyme. <i>Toxicology and Applied Pharmacology</i> , 1995, 131, 63-72.	1.3	43
219	Glutathione S-Transferase 8-8 Is Localized in Smooth Muscle Cells of Rat Aorta and Is Induced in an Experimental Model of Atherosclerosis. <i>Toxicology and Applied Pharmacology</i> , 1995, 133, 27-33.	1.3	47
220	Activity of melphalan in combination with the glutathione transferase inhibitor sulfasalazine. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 13-19.	1.1	28
221	Activity of melphalan in combination with the glutathione transferase inhibitor sulfasalazine. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 13-19.	1.1	0
222	A novel glutathione S-transferase isozyme similar to GST 8-8 of rat and mGSTA4-4 (GST 5.7) of mouse is selectively expressed in human tissues. <i>BBA - Proteins and Proteomics</i> , 1994, 1204, 279-286.	2.1	55
223	Modulation of cisplatin cytotoxicity by sulphasalazine. <i>British Journal of Cancer</i> , 1994, 70, 190-194.	2.9	40
224	Naturally Occurring Human Glutathione S-transferase GSTP1-1 Isoforms with Isoleucine and Valine in Position 104 Differ in Enzymic Properties. <i>FEBS Journal</i> , 1994, 224, 893-899.	0.2	389
225	Several Closely Related Glutathione S-Transferase Isozymes Catalyzing Conjugation of 4-Hydroxynonenal Are Differentially Expressed in Human Tissues. <i>Archives of Biochemistry and Biophysics</i> , 1994, 311, 242-250.	1.4	102
226	Gender-related differences in expression of murine glutathione S-transferases and their induction by butylated hydroxyanisole. <i>Comparative Biochemistry and Physiology C, Comparative Pharmacology and Toxicology</i> , 1994, 108, 311-319.	0.5	7
227	Adenosine triphosphate-dependent transport of doxorubicin, daunomycin, and vinblastine in human tissues by a mechanism distinct from the P-glycoprotein.. <i>Journal of Clinical Investigation</i> , 1994, 93, 958-965.	3.9	112
228	Glutathione S-transferases of human skin: qualitative and quantitative differences in men and women. <i>BBA - Proteins and Proteomics</i> , 1993, 1163, 266-272.	2.1	40
229	Interactions of glutathione S-transferase- $\gamma$ with ethacrynic acid and its glutathione conjugate. <i>BBA - Proteins and Proteomics</i> , 1993, 1164, 173-178.	2.1	116
230	Purification and Characterization of Glutathione S-Transferase of Murine Ovary and Testis. <i>Archives of Biochemistry and Biophysics</i> , 1993, 301, 143-150.	1.4	21
231	Glutathione and glutathione linked enzymes in human small cell lung cancer cell lines. <i>Cancer Letters</i> , 1993, 75, 111-119.	3.2	27
232	Phase III detoxification system. <i>Trends in Biochemical Sciences</i> , 1993, 18, 164-165.	3.7	13
233	The relationship of doxorubicin binding to membrane lipids with drug resistance. <i>Cancer Letters</i> , 1992, 63, 109-116.	3.2	26
234	Dinitrophenyl S-glutathione ATPase purified from human muscle catalyzes ATP hydrolysis in the presence of leukotrienes. <i>Archives of Biochemistry and Biophysics</i> , 1992, 298, 231-237.	1.4	40

#	ARTICLE	IF	CITATIONS
235	Glutathione S-transferases of human lung: Characterization and evaluation of the protective role of the $\Gamma$ -class isozymes against lipid peroxidation. Archives of Biochemistry and Biophysics, 1992, 299, 232-241.	1.4	114
236	Gender related differences in the expression and characteristics of glutathione S-transferases of human colon. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1992, 1171, 19-26.	2.4	36
237	Reversed-phase chromatographic method for specific determination of glutathione in cultured malignant cells. Biomedical Applications, 1992, 584, 167-173.	1.7	12
238	Activation of human erythrocyte, brain, aorta, muscle, and ocular tissue aldose reductase. Metabolism: Clinical and Experimental, 1986, 35, 114-118.	1.5	42
239	Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. International Journal of Oncology, 0, , .	1.4	18